Catalog Home Page

Psychometric Validation of the New International Questionnaire to Assess Health-Related Quality of Life (Hrql) Specific to Viral Hepatitis C: Proqol-Hcv

Duracinsky, M., Armstrong, A., Herrmann, S., Lalanne, C., Galano, E., Da Silva, M.H., Carrieri, P.M. and Chassany, O. (2015) Psychometric Validation of the New International Questionnaire to Assess Health-Related Quality of Life (Hrql) Specific to Viral Hepatitis C: Proqol-Hcv. Value in Health, 18 (7). A591-A592.

Link to Published Version: https://doi.org/10.1016/j.jval.2015.09.1523
*Subscription may be required

Abstract

Objectives
To validate a new international questionnaire to assess Health-Related Quality of Life (HRQL) in patients living with HCV. Existing tools used in HCV were mostly generic and missing important concepts such as impact of the treatment.

Methods
660 HCV mono-infected or HIV co-infected patients included in a cross-sectional survey in 3 countries (France [59%], Brazil [30%], and Australia [11%]) completed paper- or internet-based version of 3 HRQL questionnaires and symptom, sociodemographic and biomedical checklist. Psychometric item analysis and factor analysis were used to reduce the original 72-item PROQOL-HVC questionnaire. Reliability (Cronbach’s alpha), convergent validity (EQ-5D, SF-12, symptoms), and clinical validity (biological markers) were assessed on the final version using correlation and two-group comparison at a fixed 5% level.

Results
Sample characteristics: 57% men, 52 years, 80% vocational level and higher, 35% living alone. Regarding comorbidities and treatment status: 35% co-infected with VIH (95% under ART), 15% not treated, 25% undergoing interferon, 35% ribavirine, 43% Direct-Acting Antivirals (35% without associated interferon); 27% depressive (71% treated). The PROQOL-HCV questionnaire was reduced to 38 items spanning 7 dimensions scored on a 100-point scale: Physical Health (PH, 6 items, α=0.90), Emotional Health (EH, 9 items, α=0.93), Future Uncertainty (FU, 6 items, α=0.79), Intimate Relationships (IR, 3 items, α=0.86), Social Health (SH, 3 items, α=0.47), Cognitive Functioning (CF, 3 items, α=0.80), and Treatment Impact (TI, 8 items, α=0.61). Pearson correlations of PROQOL-HCV dimension with the EQ5-D (general health) and SF-12 mental and physical composites were in the acceptable range. The PH dimension was negatively correlated to the number of bothersome symptoms (p<0.001). Lower HRQL (PH, EH, CF) was reported in women (p<0.01), depressive patients (p<0.001), patients under interferon (p<0.01, except CF), patients without treatment (p<0.01).

Conclusions
PROQOL-HCV questionnaire is valid and contains new dimensions such as Intimate Relationship, Social Health and Treatment impact.

Publication Type: Journal Article
Murdoch Affiliation: Institute for Immunology and Infectious Diseases
Publisher: Elsevier Limited
Copyright: © 2015 Published by Elsevier Inc.
URI: http://researchrepository.murdoch.edu.au/id/eprint/38811
Item Control Page Item Control Page